LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "000 per" as a keyword



Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study

Sign Up to like & get
recommendations! Published in 2018 at "Journal of Neurology"

DOI: 10.1007/s00415-018-8835-6

Abstract: IntroductionAcquired demyelinating syndromes (ADS) are immune-mediated demyelinating disorders of the central nervous system in children. A nationwide, multicentre and prospective cohort study was initiated in the Netherlands in 2006, with a reported ADS incidence of… read more here.

Keywords: incidence; 000 per; study; 100 000 ... See more keywords

P103 The impact of the COVID-19 pandemic on primary care referrals and new diagnoses of inflammatory arthritis

Sign Up to like & get
recommendations! Published in 2023 at "Rheumatology"

DOI: 10.1093/rheumatology/kead104.144

Abstract: The COVID-19 pandemic abruptly changed healthcare delivery. This study describes the impact the pandemic had on time to referral and diagnosis of inflammatory arthropathies (IA), including rheumatoid arthritis (RA) and juvenile inflammatory arthritis (JIA), in… read more here.

Keywords: diagnosis; 000 per; covid; 000 000 ... See more keywords

Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease

Sign Up to like & get
recommendations! Published in 2022 at "Neurology"

DOI: 10.1212/wnl.0000000000013314

Abstract: Background and Objectives Aducanumab was granted accelerated approval with a conflicting evidence base, near-unanimous Food and Drug Administration Advisory Committee vote to reject approval, and a widely criticized launch price of $56,000 per year. The… read more here.

Keywords: cost; care; effectiveness; price ... See more keywords

Abemaciclib early access - an Italian experience

Sign Up to like & get
recommendations! Published in 2025 at "Frontiers in Oncology"

DOI: 10.3389/fonc.2025.1563844

Abstract: Italian legislation allows pharmaceutical companies to market drugs authorized through the centralized procedure before price negotiation with the Italian Medicines Agency (AIFA), placing them in the C(nn) category, which indicates non-reimbursed and non-negotiated drugs. Since… read more here.

Keywords: breast cancer; early access; abemaciclib early; 000 per ... See more keywords